Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Osteoporosis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Osteoporosis
    Long-Term Use of Alendronate Puts Some Patients at Risk for Fracture - (DGNews)
    TopAbstracts in Osteoporosis 06/24/2008 - (DGNews)
    Ultrasound Exam May Predict Risk for Fractures From Osteoporosis in Elderly Women - (DGNews)
    Canadian Study Supports Osteoporosis Screening Every 5 Years - (DGNews)
    No Link Between Ibandronate and Atrial Fibrillation in Postmenopausal Osteoporosis Patients: Presented at EULAR - (DGDispatch)

    News archive

     Recent webcasts/CME - Osteoporosis
  • Updates in the Diagnosis and Management of Osteoporosis: A Rheumatology Perspective
  • Glucocorticoid-Induced Osteoporosis: From the Bedside to the Bench and Back to the Bedside
    Guidelines for Pharmacists: Interpreting the Medical Evidence for Bisphosphonates in Postmenopausal Osteoporosis (Credit no longer available)

    Webcasts/CME archive

     Recent cases - Osteoporosis
      A Clay-Shoveler's Fracture with Renal Transplantation and Osteoporosis: A Case Report
      Stress Fracture of the Femoral Neck in a 24-Year-Old Female with Anorexia Nervosa Induced Osteoporosis
      Osteoporosis in Elderly Men
      Osteoporosis and Amenorrhea in a Young Patient with von Hippel-Lindau Disease
      Synovitis Induced by Alendronic Acid can Present as Acute Carpal Tunnel Syndrome

      Cases archive
        




      my personal edition > osteoporosis > news
      divider

        E-Mail this DGReview to a colleague

      DGReview


      Alendronate Suppresses the Beneficial Effects of Parathyroid Hormone Therapy in Men with Osteoporosis

      A DGReview of :"The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis"
      New England Journal of Medicine (NEJM)

      10/09/2003
      By Deanna M Green, PhD


      The addition of alendronate to parathyroid hormone treatment in men with osteoporosis curbs the significant increases in bone mineral density and serum alkaline phosphatase levels observed with parathyroid hormone therapy alone, say researchers.

      Alendronate is an antiresorptive bisphosphonate therapy that can increase bone mineral density and decrease the risk of fracture in patients with osteoporosis. Parathyroid hormone therapy is another treatment option for men and oestrogen-deficient women with osteoporosis, as this treatment has been shown to increase bone mineral density in these patients.

      Unlike the bisphosphonates, parathyroid hormone therapy increases both bone formation and bone resorption. It has therefore been suggested that combining parathyroid hormone therapy with the antiresorptive properties of alendronate may increase the benefits of parathyroid hormone therapy alone.

      Joel S. Finkelstein, MD, and colleagues at the Massachusetts General Hospital, Boston, United States, evaluated the use of alendronate and parathyroid hormone, alone and in combination, in the treatment of osteoporosis in men.

      The randomised study included 83 men (average age 58) with low bone mineral density that received either alendronate (10 mg daily), parathyroid hormone (40 ug subcutaneously daily), or combinatorial therapy for 30 months. Notably, parathyroid hormone therapy was not initiated until the sixth month of the study.

      Bone mineral density of the lumbar spine, proximal femur, radial shaft, and total body was measured by dual-energy x-ray absorptiometry every 6 months. Serum alkaline phosphatase levels were also measured at these times.

      Overall, bone mineral density in the lumbar spine and femoral neck increased significantly higher in those treated with parathyroid hormone alone than in those given alendronate alone. Furthermore, combinatorial therapy also showed greater effects on bone mineral density than alendronate alone.

      Interestingly, parathyroid hormone therapy alone was more effective at increasing bone mineral density than combinatorial therapy, indicating that the addition of alendronate actually suppressed parathyroid hormone therapy's beneficial effects.

      Results also indicated that serum alkaline phosphatase levels increased significantly in patients receiving only parathyroid hormone therapy. In contrast, levels decreased in the alendronate alone group and remained steady in the combination group after 12 months.

      Reports of headache, dizziness, and joint pain were significantly higher in patients receiving parathyroid hormone therapy as compared to those receiving only alendronate. Furthermore, significantly more men receiving parathyroid hormone therapy discontinued the study, the most common reason being discomfort or inconvenience related to injections.

      The authors conclude that "alendronate impairs the ability of parathyroid hormone to increase bone mineral density at the lumbar spine and femoral neck in men with osteoporosis." They further note that "additional studies are needed before combinations of antiresorptive agents and parathyroid hormone can be recommended for the treatment of men with osteoporosis."


      N Engl J Med 2003 Sep 25;349:13:1216-26. "The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis"

      E-Mail this DGReview to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send